Erratum: A miRNA-based signature predicts development of disease recurrence in HER2 positive breast cancer after adjuvant trastuzumab-based treatment

Sci Rep. 2016 Oct 14:6:35509. doi: 10.1038/srep35509.
No abstract available

Publication types

  • Published Erratum